Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Key claim: Post-MPN AML treated with intensive 7+3 induction has particularly dismal outcomes (27% CR/CRi; 0% 5-year transplant-censored survival) and should be prognostically separated from post-MDS AML, while routine NGS mutation risk is mostly informative only in primary non-CBF AML.
Abstract
We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015-2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow-up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core-binding factor (CBF; N = 72; 13%), primary non-CBF (N = 403; 74%), post-myelodysplastic syndromes (MDS) or post-myelodysplastic/myeloproliferative neoplasms (post-MDS-MDS/MPN; N = 28; 5%), post-MPN (N = 15; 3%), and therapy-related (t-AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% (p < 0.01) and 5-year transplant-censored survival rates 68%, 57%, 21%, 0%, and 55% (p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non-CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3-ITD (OR 0.4; p < 0.01) or NPM1/FLT3(OR 0.1; p < 0.01) superior CR/CRi while KRAS(HR 8.8; p < 0.01), TP53(HR 5.4; p < 0.01), and TET2(HR 2.3; p = 0.01) predicted inferior and NPM1/FLT3(HR 0.3; p = 0.01) superior survival. Prognostication in intensively-treated AML should start with subtype specification and recognition of the limited value of NGS in non-primary AML. Post-MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post-MDS-MDS/MPN AML. In primary non-CBF AML, in addition to previously established risk factors, the favorable impact of FLT3-ITD on achieving CR/CRi and the unfavorable impact of KRASand TET2on transplant-censored survival were noted and require confirmation from additional studies.
Why this matters
This finding sharpens the decision-layer argument for earlier transplant referral in MPN: once progression to post-MPN AML occurs, intensive 7+3 induction produces low remission rates and essentially no long-term survival without transplant, and NGS-based risk stratification (which drives many AML treatment decisions) adds little in this subtype. It reframes post-MPN AML as a distinct, worse-prognosis entity from post-MDS AML and reinforces that the transplant window should be captured before blast-phase transformation rather than relying on salvage induction afterward.